Iterex is a digital therapeutics company that - using artificial intelligence - is designed to empower patients towards a level of self-management of their chronic lung or cardiovascular condition signs and symptoms. Users of the firm's system get on-demand, cost-effective, personalized assessments of their condition at the most critical moments in their lives. Engaging a built-in machine learning feature to detect and treat flare-ups of chronic heart and lung illnesses., use of the system helps patients interpret troubling symptoms and signs with the goal of finding the right level of care earlier in their illness, Since Febraury 2019, the firm has been working with AstraZenecas Innovative Medicine and Early Development (IMED) Biotech Unit in respiratory clinical trials to evaluate CompEx, a novel therapeutic endpoint for asthma. CompEx is an algorithm combining patient-recorded lung function deterioration, symptoms and use of reliever medication with the traditional measurement of severe exacerbations. Use of Iterexs technology is reoorted as enabling AZ to conduct real-time assessments of CompEx events and to evaluate how these correlate with patient health escalations, medication usage, and Iterexs machine-learned triage prediction.
